1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, M0
Market cap: $57.2B (2/09/2026)
Price: $18.10
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Earnings Report for the Nine-month Period Ended December 31, 2025
Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Protagonist Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Business Report: The 149th Interim Period
Files Semi-annual Securities Report
Earnings Report (Kessan Tanshin) for the Six-month Period Ended September 30, 2025
Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
Annual and Transition Report of Foreign Private Issuers
Prospectus Filed Pursuant to Rule 424(b)(2)
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Certificate
No filings found
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Quarterly Holdings Report for Institutional Managers
Annual Report of Proxy Voting Record
Free Writing Prospectus
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Specialized Disclosure Report